Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Article Information
- Received August 17, 2017
- Accepted in final form October 3, 2017
- First Published December 28, 2017.
Author Disclosures
- Maryam Nakhaei-Nejad, PhD,
- David Barilla, Dip,
- Chieh-Hsin Lee, BSc,
- Gregg Blevins, MD and
- Fabrizio Giuliani, MD
- Maryam Nakhaei-Nejad, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Barilla, Dip,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Chieh-Hsin Lee, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gregg Blevins, MD and
Served on Advisory boards for Biogen Idec, Teva Pharmaceuticals, Novartis, Genzyme, Roche and EMD Serono/Merck from 2006-present
NONE
Received travel funding through Biogen Idec, Teva Pharmaceuticals, Novartis, Genzyme, Roche and EMD Serono/Merck from 2006-present
NONE
NONE
NONE
Self-employed
Have received consulting fees from Biogen Idec, Teva Pharmaceuticals, Novartis, Genzyme, Roche and EMD Serono/Merck from 2006-present
NONE
NONE
NONE
NONE
Canadian Institute for Health Research, Alberta Innovates, Canadian Foundation for Innovation
NONE
Multiple Sclerosis Society of Canada
NONE
NONE
NONE
NONE
NONE
NONE
- Fabrizio Giuliani, MD
(1)Alberta MS Network (non-profit)
NONE
(1)Merck-Serono, honoraria (2)Biogen, honoraria (3)Genzyme, honoraria (4)Roche, honoraria
NONE
NONE
NONE
NONE
(1)Merck-Serono (2)Biogen (3)Genzyme (4)Roche
NONE
NONE
NONE
(1)Biogen Canada
(1)Alberta Ministry of Innovation and Advanced Education,AE-2014-0065, Principal Investigator,4 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Correspondence to Dr. Giuliani: fabrizio.giuliani{at}ualberta.ca
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Effect of dimethyl fumarate on lymphocytes in RRMSImplications for clinical practiceDevangi Mehta, Catherine Miller, Douglas L. Arnold et al.Neurology, March 27, 2019 -
Article
Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosisMahtab Ghadiri, Ayman Rezk, Rui Li et al.Neurology: Neuroimmunology & Neuroinflammation, March 23, 2017 -
Article
Low frequencies of central memory CD4 T cells in progressive multifocal leukoencephalopathyEvelyn Dubois, Christoph Ruschil, Felix Bischof et al.Neurology - Neuroimmunology Neuroinflammation, October 29, 2015 -
Review
Lymphopenia and DMTs for relapsing forms of MSConsiderations for the treating neurologistEdward J. Fox, Guy J. Buckle, Barry Singer et al.Neurology: Clinical Practice, January 08, 2019